Astellas has floored the accelerator on an immuno-oncology R&D project, putting down $20.5 million to team up with GO Therapeutics in a race to find antibodies with high affinity to two different glycoprotein targets.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,